Abstract / Summary
To systematically evaluate the diagnostic performance of miRNA panels for endometrial cancer. PubMed, Web of Science, CNKI, Embase, and VIP were searched for eligible studies published through 2025. Study quality was assessed using QUADAS-2. Pooled sensitivity, specificity, diagnostic odds ratio (DOR), and the area under the summary receiver operating characteristic curve (AUC) were calculated using Meta-Disc 1.4, Review Manager 5.3, and Stata 17.0. Nine primary studies involving 531 participants and 9 independent diagnostic models were included. The pooled diagnostic score was 4.78 (95% CI: 3.86-5.71), and the pooled DOR was 119.50 (95% CI: 47.49-300.70). The pooled sensitivity and specificity were 0.90 (95% CI: 0.81-0.95) and 0.93 (95% CI: 0.89-0.96), respectively. The AUC was 0.94 (95% CI: 0.92-0.96). Subgroup analyses indicated that geographic region and sample type might contribute to heterogeneity. miRNA panels show good diagnostic accuracy for endometrial cancer, with high sensitivity, specificity, and overall discriminatory ability. However, substantial heterogeneity and methodological limitations require cautious interpretation, and further large-scale prospective studies are needed before routine clinical application.
Primary Source
Journal of lower genital tract disease
Ask Prognia AI
Have questions about this meta-analysis?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.